2025 Q4 -tulosraportti
66 päivää sitten
‧44 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 819 | - | - | ||
| 71 681 | - | - | ||
| 48 701 | - | - | ||
| 23 264 | - | - | ||
| 250 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·8 t sitten · MuokattuIt will be exciting to see if we ever beat previous ath here, then it would have made money for us who are now getting in under a krona... I myself have a GAV of 0.2, have a continued nice Saturday:-)
·12 t sittenI have this stock, potential? And could someone share links about this stock?
·11 t sittenShort answer: Yes, there is enormous potential and upside – but with that potential also comes risk. The company's main project has presented outstanding data in a Phase 2 study, which has received significant attention. They are now preparing for a Phase 3 study, which will be very costly, and this is where the biggest risk lies. New share issues are common in biotech when capital needs to be raised, and that is the primary reason for the low market capitalization right now. An alternative is partnership agreements with larger pharmaceutical companies, which can secure funding for the Phase 3 study. This is also something many investors speculate about and an important explanation for the recent share price increase. The hope is that the recently published news signals increased interest from larger pharmaceutical companies to enter into partnerships.
·14 t sitten · MuokattuNow corrected for calculation error: As a reference point, I have calculated what the average price is for 1 share if one started by buying 1 unit (2 shares) in connection with the new issue around February 2024 when a positive result from the phase 2 study was already known. I.e., 1000 shares at 1.07 SEK + 1000 shares at 0.55 SEK (TO9), which today would be 2 shares at a unit price of 810 SEK. If one with this position has since participated pro-rata in all new issues, then today one would have a total position of 748 shares with an average cost basis of 3.8 SEK per share. There is thus a good way up before the average invested value over the last 2 years is reached. Does anyone arrive at the same conclusion? Has anyone looked further back?
·1 päivä sittenThis was positive * 100 % of patients show immune response (6/6) * increased number of neoantigen responses in several patients * combination (IRE + CD40) shows "systemic effect"-signal * PDAC is an extremely difficult area → even small signals can be interpreted positively 👉 This gives a "bull case": the mechanism works in humans- ·1 päivä sittenThis is what I have found, don't know if it's right or not so you have to do your own research. But both I and AI interpret this data positively, hopefully it will be strengthened by pressentation and PM in the coming days. Link below: https://aacrjournals.org/cancerres/article/86/8_Supplement/CT089/782817/Abstract-CT089-Irreversible-electroporation-IRE?searchresult=1
·18 t sitten · MuokattuHave tried to find more info than this abstract, but no hits in any databases. Would have liked to read up more. This is a very small population and would have liked to know more about the inclusion/exclusion criteria. And would have liked to know a bit more about patient number 5. But absolutely exciting to follow going forward.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
66 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sitten · MuokattuIt will be exciting to see if we ever beat previous ath here, then it would have made money for us who are now getting in under a krona... I myself have a GAV of 0.2, have a continued nice Saturday:-)
- ·12 t sittenI have this stock, potential? And could someone share links about this stock?·11 t sittenShort answer: Yes, there is enormous potential and upside – but with that potential also comes risk. The company's main project has presented outstanding data in a Phase 2 study, which has received significant attention. They are now preparing for a Phase 3 study, which will be very costly, and this is where the biggest risk lies. New share issues are common in biotech when capital needs to be raised, and that is the primary reason for the low market capitalization right now. An alternative is partnership agreements with larger pharmaceutical companies, which can secure funding for the Phase 3 study. This is also something many investors speculate about and an important explanation for the recent share price increase. The hope is that the recently published news signals increased interest from larger pharmaceutical companies to enter into partnerships.
- ·14 t sitten · MuokattuNow corrected for calculation error: As a reference point, I have calculated what the average price is for 1 share if one started by buying 1 unit (2 shares) in connection with the new issue around February 2024 when a positive result from the phase 2 study was already known. I.e., 1000 shares at 1.07 SEK + 1000 shares at 0.55 SEK (TO9), which today would be 2 shares at a unit price of 810 SEK. If one with this position has since participated pro-rata in all new issues, then today one would have a total position of 748 shares with an average cost basis of 3.8 SEK per share. There is thus a good way up before the average invested value over the last 2 years is reached. Does anyone arrive at the same conclusion? Has anyone looked further back?
- ·1 päivä sittenThis was positive * 100 % of patients show immune response (6/6) * increased number of neoantigen responses in several patients * combination (IRE + CD40) shows "systemic effect"-signal * PDAC is an extremely difficult area → even small signals can be interpreted positively 👉 This gives a "bull case": the mechanism works in humans
- ·1 päivä sittenThis is what I have found, don't know if it's right or not so you have to do your own research. But both I and AI interpret this data positively, hopefully it will be strengthened by pressentation and PM in the coming days. Link below: https://aacrjournals.org/cancerres/article/86/8_Supplement/CT089/782817/Abstract-CT089-Irreversible-electroporation-IRE?searchresult=1·18 t sitten · MuokattuHave tried to find more info than this abstract, but no hits in any databases. Would have liked to read up more. This is a very small population and would have liked to know more about the inclusion/exclusion criteria. And would have liked to know a bit more about patient number 5. But absolutely exciting to follow going forward.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 819 | - | - | ||
| 71 681 | - | - | ||
| 48 701 | - | - | ||
| 23 264 | - | - | ||
| 250 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
2025 Q4 -tulosraportti
66 päivää sitten
‧44 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 23.10.2025 | ||
2025 Q2 -tulosraportti 10.7.2025 | ||
2025 Q1 -tulosraportti 24.4.2025 | ||
2024 Q4 -tulosraportti 22.1.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·8 t sitten · MuokattuIt will be exciting to see if we ever beat previous ath here, then it would have made money for us who are now getting in under a krona... I myself have a GAV of 0.2, have a continued nice Saturday:-)
- ·12 t sittenI have this stock, potential? And could someone share links about this stock?·11 t sittenShort answer: Yes, there is enormous potential and upside – but with that potential also comes risk. The company's main project has presented outstanding data in a Phase 2 study, which has received significant attention. They are now preparing for a Phase 3 study, which will be very costly, and this is where the biggest risk lies. New share issues are common in biotech when capital needs to be raised, and that is the primary reason for the low market capitalization right now. An alternative is partnership agreements with larger pharmaceutical companies, which can secure funding for the Phase 3 study. This is also something many investors speculate about and an important explanation for the recent share price increase. The hope is that the recently published news signals increased interest from larger pharmaceutical companies to enter into partnerships.
- ·14 t sitten · MuokattuNow corrected for calculation error: As a reference point, I have calculated what the average price is for 1 share if one started by buying 1 unit (2 shares) in connection with the new issue around February 2024 when a positive result from the phase 2 study was already known. I.e., 1000 shares at 1.07 SEK + 1000 shares at 0.55 SEK (TO9), which today would be 2 shares at a unit price of 810 SEK. If one with this position has since participated pro-rata in all new issues, then today one would have a total position of 748 shares with an average cost basis of 3.8 SEK per share. There is thus a good way up before the average invested value over the last 2 years is reached. Does anyone arrive at the same conclusion? Has anyone looked further back?
- ·1 päivä sittenThis was positive * 100 % of patients show immune response (6/6) * increased number of neoantigen responses in several patients * combination (IRE + CD40) shows "systemic effect"-signal * PDAC is an extremely difficult area → even small signals can be interpreted positively 👉 This gives a "bull case": the mechanism works in humans
- ·1 päivä sittenThis is what I have found, don't know if it's right or not so you have to do your own research. But both I and AI interpret this data positively, hopefully it will be strengthened by pressentation and PM in the coming days. Link below: https://aacrjournals.org/cancerres/article/86/8_Supplement/CT089/782817/Abstract-CT089-Irreversible-electroporation-IRE?searchresult=1·18 t sitten · MuokattuHave tried to find more info than this abstract, but no hits in any databases. Would have liked to read up more. This is a very small population and would have liked to know more about the inclusion/exclusion criteria. And would have liked to know a bit more about patient number 5. But absolutely exciting to follow going forward.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 819 | - | - | ||
| 71 681 | - | - | ||
| 48 701 | - | - | ||
| 23 264 | - | - | ||
| 250 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt